Peredox Digital

building.

[Jay Peredo @jayperedox]

I bet you’d actually FEEL bodega peptides

[PepTracker App @PepTracker]

Retatrutide hit 28.3% weight loss at the top dose but 19% at 4mg is the practical story.

Meaningful loss at one titration step means more people actually stay on it...

and that tells you more about what this drug looks like in real life than any headline number.

[Jay Peredo @jayperedox]

retatrutide WILL become the #1 selling drug in the world.

[PepTracker App @PepTracker]

Most people don’t know why retatrutide’s results are so different from semaglutide or tirzepatide.

It comes down to receptors.

Semaglutide targets one.

Tirzepatide targets two.

Retatrutide targets three - adding glucagon to the mix, which accelerates fat burning in ways the others can’t.

Each receptor added has moved the needle significantly. The Phase 3 results reflect that.

[Jay Peredo @jayperedox]

back on retatrutide after a 4 week break 💪

[PepTracker App @PepTracker]

RFK has been saying this was coming for weeks. Now it’s official.

The FDA is removing 12 peptides from the restricted list. BPC-157, MOTS-c, Semax, Epitalon, Thymosin beta-4 among them. Independent scientific review begins in July.

People have been sourcing these through grey markets for years because legitimate access was cut off. That’s what created real risk for real people.

This should never have happened in the first place.

[PepTracker App @PepTracker]

GLP-1s are doing a lot more than suppressing appetite and the data reflects that.

This is why tracking your protocol matters.

[PepTracker App @PepTracker]

The FDA is expected to lift its ban on injectable peptides from compounding pharmacies.

The regulatory tide is finally shifting.

[PepTracker App @PepTracker]

Eli Lilly's orforglipron just got approved as the first GLP-1 pill for weight loss.

A lot of people who passed on injections are about to reconsider.

The barrier to entry just got a lot lower.

[Jay Peredo @jayperedox]

Peptide Sciences shutting down isn’t the story.

The story is the peptide market shifting underneath it.

When access moves from research vendors to compounding pharmacies, the ecosystem changes.

Some companies disappear.

New ones replace them.

[PepTracker App @PepTracker]

Peptide Sciences, arguably one of the largest research peptide vendors, just announced they’re shutting down.

That’s a pretty big deal considering how long they’ve been around.

It also likely won’t be the last.

As compounding pharmacies gain clearer pathways to prescribe peptides, the old “research peptide” vendor model becomes harder to sustain.

A few things worth knowing:

- This doesn’t mean peptides are going away
- Some gray-market vendors will likely disappear
- New ones will also show up quickly

When a big vendor disappears, the market doesn’t disappear.

It fragments.

[Jay Peredo @jayperedox]

The peptide gray market will never go away.

There’s already so many compounding pharmacies selling crazy marked up peptides they also bought from the gray market.

[PepTracker App @PepTracker]

If this plays out, we’re entering a more regulated phase of the peptide market…but that doesn’t necessarily make it simpler.

Gray markets don’t disappear overnight.

They evolve.

Access and enforcement often expand at the same time.

That increases fragmentation.

More vendors.
More supply channels.
More variability.
More room for protocol error.

Regulation may improve oversight.

It doesn’t remove execution complexity.

Access gets attention.

Structure determines outcomes.

[Jay Peredo @jayperedox]

Incoming peptide frenzy 👀

[PepTracker App @PepTracker]

RFK Jr. was just on Joe Rogan’s podcast and said ~14 peptides currently restricted under the FDA’s Category 2 list could soon be eligible for legal compounding again.

If implemented, that would materially EXPAND peptide access in the U.S.

Category 2 status currently restricts compounding due to safety concerns.

Moving substances to Category 1 would allow regulated U.S. pharmacies to compound them under oversight, potentially reducing reliance on unregulated sourcing.

Access expansion changes behavior quickly.

If more peptides become legally compoundable, we’ll likely see:

- More first-time users
- More stacking
- Faster experimentation
- More telehealth activity

But increased availability doesn’t automatically improve outcomes.

More compounds in circulation often means:

- Overlapping protocols
- Escalation mistakes
- Inconsistent cycles
- Less clarity on what’s actually working

Regulatory shifts may improve supply chain oversight.

They don’t replace execution discipline.

Whether 14 peptides move or not, one variable remains constant:

Outcomes depend on structured use.

Clear protocols.
Intentional dosing.
Consistent tracking.

If peptide access expands, structured protocol management becomes even more important.

That’s exactly why PepTracker exists.

[Jay Peredo @jayperedox]

The biggest GLP-1 breakthrough won’t be a stronger molecule.

It’ll be better adherence.

Pills increase access.

Systems increase outcomes.

[PepTracker App @PepTracker]

Lilly’s oral GLP-1 (orforglipron) outperformed oral semaglutide in A1C and weight loss in a head-to-head T2D trial published in The Lancet.

This is meaningful comparative data.

But let’s add some context… 👇

[PepTracker App @PepTracker]

If your friends aren’t talking about:

- Peptides
- And how to track them

Time to find new friends (and download us)

[PepTracker App @PepTracker]

New week starts tonight. Make sure your peptide schedule is on track and ready!

[PepTracker App @PepTracker]

Impressive trial data! As with any protocol, accurate dosing and consistency can make all the difference.

The GLP-1 space is only going to keep growing. Great time to be paying attention 🫡